Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970686 | 0.94 | GAA (0.61) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL15131652 | 0.85 | GAA (0.52) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL20814490 | 0.84 | GAA (0.75) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL11451349 | 0.84 | GAA (0.45) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL8041736 | 0.82 | GAA (0.74) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL24059309 | 0.80 | MAPK1 (0.50) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL13208246 | 0.80 | GAA (0.58) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL18680108 | 0.75 | L3MBTL1 (0.49) | GAATDP1KMT2AALDH1A1MEN1 | |
| SCHEMBL12410776 | 0.74 | LMNA (0.52) | GAATDP1HTTMAPK1LMNA | |
| SCHEMBL20117984 | 0.72 | GAA (0.61) | GAATDP1HTTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064923-A9 | COVALENT, CHEMOGENETIC ACTIVATORS FOR K2P POTASSIUM CHANNELS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2013166358-A1 | SURFACE COATINGS FOR BIOLOGICAL IMPLANTS AND PROSTHESES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | GAA 148/4885TDP1 2216/4885HTT 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.